On January 23, 2026, GUSHENGTANG Chinese Medicine Group (02273) officially launched the "GUSHENGTANG Chinese Medicine Education and Research Program" with Singapore's Nanyang Technological University (NTU), aiming to promote the training of Chinese medicine professionals and the development of evidence-based research in Singapore, thereby contributing to the local healthcare ecosystem. The signing ceremony was witnessed by Senior Minister of State for Communications and Information & Health of Singapore, Mr. Tan Kiat How (second from left, back row), Chairman of the Singapore Traditional Chinese Medicine Practitioners Board, Dr. Zhang Hubin (first from left, back row), Chairman of GUSHENGTANG Chinese Medicine Group, Mr. Tu Zhiliang (second from right, back row), and NTU Senior Vice-President (Administration), Ms. Chan Yit Foon (first from right, back row). The ceremony was held in a hybrid online and offline format, with a domestic branch venue in China facilitating simultaneous academic exchange.
This collaboration signifies that GUSHENGTANG's multi-dimensional "Academic + Technology + Capital" global expansion model has become a structured system, forming a mutually reinforcing strategic triangle. Academically, it will leverage NTU's top-tier research capabilities to jointly initiate evidence-based research in Chinese medicine and talent development. Technologically, GUSHENGTANG will continue to promote the innovative application of cutting-edge technologies like AI and big data in the field of Chinese medicine. Capital-wise, GUSHENGTANG has successfully secured a strategic investment from the renowned Singaporean investment firm AGP, providing strong momentum for the industrialization of Chinese medicine in Singapore.
Mr. Tu Zhiliang, Founder and Chairman of GUSHENGTANG Chinese Medicine Group, stated, "Singaporeans highly recognize Chinese medicine, with the patient revisit rate in Singapore ranking first across the entire group over the past year. The collaboration with Nanyang Technological University is not only a deep cross-border partnership but also a crucial step in the internationalization of Chinese medicine. Through an integrated 'Education-Clinical-Research-Industry' model, we will systematically promote the localization of Chinese medicine in Singapore, enabling it to play a greater role in the modern healthcare system."
NTU Senior Vice-President Ms. Chan Yit Foon pointed out, "NTU has been continuously investing in the cultivation of Chinese medicine talent for the past two decades. This collaboration will help further enhance teaching quality, deepen research outcomes, and promote the long-term development of TCM professionals."
As the academic pillar of GUSHENGTANG's multi-dimensional expansion model, this strategic cooperation with NTU achieves a deep integration of a top academic institution and a high-quality healthcare service provider. Facing challenges like population aging and growing healthcare demands, Singaporean society's focus on preventive medicine and complementary therapies is increasing, highlighting the role of Chinese medicine. This collaboration aligns closely with Singapore's national healthcare priorities, such as healthy aging and chronic disease management, and will precisely focus on the two core pillars of talent and research.
In talent cultivation, by inviting top Chinese medicine experts from China for lectures, establishing doctoral scholarships, and creating overseas exchange programs, an international joint training system for TCM talent will be built. This promotes the localized application of advanced diagnostic and treatment techniques, cultivating TCM professionals with both expertise and an international perspective for the local market. Regarding research collaboration, leveraging NTU's research strengths and GUSHENGTANG's extensive clinical network, the two parties will jointly conduct evidence-based research meeting international standards, promote the application of real-world clinical data, and enhance the scientific credibility of Chinese medicine.
During academic reports held concurrently with the project launch, two renowned Chinese medicine experts from Guangdong Province shared clinical research findings, providing a high-quality platform for Sino-Singapore TCM exchange. Professor Huang Suiping systematically explained the theory of the "Fortify the Earth" school, using cases like gastric precancerous lesions, chronic gastritis, and post-operative care for tumor patients to demonstrate the unique value of spleen-strengthening and stomach-benefiting methods in chronic disease management. Professor Li Yunying proposed the "Three-Principle Pattern Differentiation" method for tinnitus diagnosis and treatment, emphasizing personalized treatment concepts and demonstrating practical aspects of non-drug interventions like five-tone therapy and ear acupoint massage. The lively on-site discussion saw constructive dialogue between Chinese and Singaporean practitioners on topics like optimizing TCM indications for specific populations in Singapore and integrated Chinese-Western medicine models.
The inheritance and standardization of TCM clinical experience are key challenges for its internationalization, and technology is GUSHENGTANG's crucial tool for solving this problem and empowering its multi-dimensional expansion. GUSHENGTANG has deeply cultivated the digitalization of TCM, using big data and AI to digitally capture the diagnostic thinking and clinical experience of top-tier experts, including Master of Traditional Chinese Medicine and nationally renowned TCM physicians, creating AI avatars of these masters and an intelligent "TCM Brain" assisted diagnosis and treatment system.
To date, GUSHENGTANG has released digital avatars of 14 top TCM experts, constructing an AI-assisted TCM diagnosis and treatment matrix with scalable service capabilities, continuously expanding the global supply of high-quality TCM resources. The GUSHENGTANG "TCM Brain" AI avatars provide a "dual empowerment" for overseas TCM development: acting as an "intelligent assistant" to help practitioners handle routine tasks, significantly improving efficiency; and serving as an "intelligent mentor" for junior physicians worldwide, aiding in study, diagnosis, and prescription reference, building a comprehensive, accompanying intelligent support system that effectively shortens the TCM training cycle.
Leveraging GUSHENGTANG's internet hospital platform, TCM practitioners in Singapore and Southeast Asia can remotely learn the clinical reasoning of China's top experts. Through practical use of AI-assisted diagnosis, they can gradually master the essence of TCM pattern differentiation, fundamentally enhancing the quality of TCM services overseas. Currently, the "TCM Brain" has begun internal pilot operations in key specialties like gastroenterology, oncology, and ENT, with dozens of junior physicians globally participating in the first deep trials, laying a solid technical and practical foundation for its entry into the Singapore market.
Building on the academic foundation and technological empowerment, capital acts as a key accelerator for GUSHENGTANG's internationalization, providing solid financial and resource support for the multi-dimensional expansion model. In October 2025, GUSHENGTANG reached a strategic cooperation with the renowned Singaporean financial investment firm AGP (August Global Partners). AGP made a direct strategic investment in GUSHENGTANG's Singapore company, with funds specifically earmarked for advancing GUSHENGTANG's international strategy and the R&D of AI-powered TCM technologies, injecting strong momentum into its global healthcare industry layout.
Since entering the Singapore market in 2024, GUSHENGTANG has experienced rapid growth, operating 16 TCM clinics across the island by December 2025, with plans to expand to 50 clinics by the end of 2026, achieving scaled coverage of the local TCM service network. This move into TCM education and research further demonstrates GUSHENGTANG's strategic intent to position Singapore as a core hub for its long-term regional development, a base for TCM innovation, and a benchmark international market.
The strategic collaboration between GUSHENGTANG and Nanyang Technological University marks a significant milestone in the international development of Chinese medicine. Seizing this opportunity, GUSHENGTANG deeply integrates the three key elements of academia, technology, and capital, forming its unique multi-dimensional "Academic + Technology + Capital" global expansion model for TCM. This is conducive to enhancing the status and credibility of TCM within Singapore's healthcare system, thereby helping TCM gain global recognition as a complementary medical system. In the future, GUSHENGTANG will continue to use Singapore as a core pivot, radiating out to Southeast Asia and global markets, continually injecting new vitality into the internationalization of Chinese medicine and contributing TCM's strengths to the global healthcare ecosystem.
Comments